Advice
in the absence of a submission from the holder of the marketing authorisation:
imipenem/cilastatin/relabactam (Recarbrio®) is not recommended for use within NHSScotland.
Indication under review: For the treatment of:
- hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults
- bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice621KB (PDF)
Medicine details
- Medicine name:
- imipenem/cilastatin/relabactam (Recarbrio)
- SMC ID:
- SMC2342
- Indication:
Indication under review: For the treatment of:
- hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults
- bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Respiratory system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 February 2021